A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Corona Virus Infection
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: BlindedPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Study duration per participant is approximately 28 days including a 14-day treatment period
Study duration per participant is approximately 28 days including a 14-day treatment period
Tracking Information
- NCT #
- NCT04622332
- Collaborators
- Not Provided
- Investigators
- Study Director: Simon Li, MD, PhD Sironax USA, Inc.
Get Well Soon